piperacillin has been researched along with zithromax in 16 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (6.25) | 18.2507 |
2000's | 6 (37.50) | 29.6817 |
2010's | 6 (37.50) | 24.3611 |
2020's | 3 (18.75) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Alba, V; Blasco, MD; Espinal, P; Fernández-Cuenca, F; Marti, S; Pascual, A; Ruiz, M; Sánchez-Céspedes, J; Vila, J | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bojkovic, J; Dean, CR; Dobler, M; Dzink-Fox, J; Glick, M; Hamann, LG; Kerrigan, J; Lanieri, L; Lenoir, F; Lilly, MD; Liu, E; Lu, Y; McKenney, D; Nunez, J; Osborne, C; Parker, DT; Patnaik, A; Peng, Y; Piizzi, G; Ranjitkar, S; Sprague, ER; Tommasi, R; Wang, B; Wang, H; Wattanasin, S; Xie, L; Yang, X; Yu, D | 1 |
Erwin, ME; Jones, RN; Worth, S | 1 |
Adam, HJ; Laing, N; Mayer, M; Zhanel, GG | 1 |
Debbia, EA; Gualco, L; Maioli, E; Marchese, A | 1 |
Andukuri, VG; Iguidbashian, JP; Kukrety, S; Parekh, JD | 1 |
Nakahashi, H; Nakura, Y; Nomiyama, M; Ono, T; Tanaka, S; Tokuda, T; Tsumura, K; Yamamoto, T; Yanagihara, I | 1 |
Jacqz-Aigrain, E; Leroux, S; Magréault, S; Storme, T; Touati, J | 1 |
Eller, P; Prattes, J; Reisinger, AC; Schilcher, G; Zollner-Schwetz, I | 1 |
Güler, N; Süleyman, A; Tamay, Z | 1 |
Aral, M; Ates, S; Doganer, A; Nazik, S; Orak, F; Yalcinkaya, KT | 1 |
1 review(s) available for piperacillin and zithromax
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
15 other study(ies) available for piperacillin and zithromax
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Sequence Analysis, DNA | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Chemistry Techniques, Synthetic; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Female; Hep G2 Cells; Humans; K562 Cells; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship | 2017 |
Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical
Topics: Acetamides; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Azithromycin; Clavulanic Acids; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Naphthyridines; Oxazoles; Oxazolidinones; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality Control; Roxithromycin; Ticarcillin | 1996 |
Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftazidime; Colistin; Dose-Response Relationship, Drug; Drug Synergism; In Vitro Techniques; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Mutation; Ofloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins; Tobramycin | 2006 |
In vitro interaction between mecillinam and piperacillin-tazobactam in the presence of azithromycin against members of the Enterobacteriaceae family and Pseudomonas aeruginosa.
Topics: Amdinocillin; Anti-Bacterial Agents; Azithromycin; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2008 |
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Campylobacter Infections; Coinfection; Colitis, Ulcerative; Feces; Female; Fever; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Sigmoidoscopy; Treatment Outcome | 2018 |
New antibiotic regimen for preterm premature rupture of membrane reduces the incidence of bronchopulmonary dysplasia.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Azithromycin; Bronchopulmonary Dysplasia; Cefmetazole; Clindamycin; Drug Therapy, Combination; Female; Fetal Membranes, Premature Rupture; Humans; Incidence; Outcome Assessment, Health Care; Piperacillin; Pregnancy; Retrospective Studies; Sulbactam | 2019 |
UPLC/MS/MS assay for the simultaneous determination of seven antibiotics in human serum-Application to pediatric studies.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Blood Chemical Analysis; Calibration; Cefotaxime; Child; Child, Preschool; Chromatography, High Pressure Liquid; Ciprofloxacin; Escherichia coli Infections; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Limit of Detection; Male; Meropenem; Metronidazole; Pediatrics; Piperacillin; Reproducibility of Results; Tandem Mass Spectrometry | 2019 |
Acute respiratory distress syndrome during a pandemic-an obvious diagnosis?
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Humans; Male; Pandemics; Piperacillin; Psittacosis; Respiratory Distress Syndrome; Tazobactam | 2020 |
Antibiotic allergy in children with cystic fibrosis: A retrospective case-control study.
Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Case-Control Studies; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Humans; Levofloxacin; Meropenem; Piperacillin; Retrospective Studies; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
The Relationship of Comorbid Diseases and Empirical Antibiotic Usage with Superinfection in COVID-19 Patients.
Topics: Anti-Bacterial Agents; Azithromycin; COVID-19; Humans; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Superinfection | 2023 |